Life Science Investing Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Life Science Investing Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
Life Science Investing Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis
Life Science Investing Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis and Systemic Lupus Erythematosus
Life Science Investing Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Life Science Investing Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
Life Science Investing Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference
Life Science Investing Adicet Bio Announces First Systemic Sclerosis Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
life science investing Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference
life science investing Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
life science investing Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
life science investing Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy 28th Annual Meeting
